Long-term efficacy of a new, fixed, very-low-dose angiotension converting enzyme inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients

被引：0
|
作者：
George Mansour
Janette Mansour
机构：
来源：
Current Hypertension Reports | 2001年 / 3卷 / 6期
关键词：
Essential Hypertension; Perindopril; Systolic Hypertension; Indapamide; Moderate Essential Hypertension;
D O I：
10.1007/s11906-001-0016-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：524 / 524
相关论文
共 39 条
  • [31] Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage
    Bomback, A. S.
    Muskala, P.
    Bald, E.
    Chwatko, G.
    Nowicki, M.
    CLINICAL NEPHROLOGY, 2009, 72 (06) : 449 - 456
  • [32] C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma
    Klumper, Niklas
    Schmucker, Philipp
    Hahn, Oliver
    Hoh, Benedikt
    Mattigk, Angelika
    Banek, Severine
    Ellinger, Jorg
    Heinzelbecker, Julia
    Sikic, Danijel
    Eckstein, Markus
    Strauss, Arne
    Zengerling, Friedemann
    Holzel, Michael
    Zeuschner, Philip
    Kalogirou, Charis
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (12)
  • [33] Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
    Li, Haixia
    Wang, Chenyu
    Wang, Ziqi
    Hu, Yabo
    Zhang, Guowei
    Zhang, Mina
    Zheng, Xuanxuan
    Zhang, Xiaojuan
    Yang, Jinbo
    Ma, Zhiyong
    Wang, Huijuan
    LUNG CANCER, 2019, 130 : 42 - 49
  • [34] An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in Chinese patients with mild to moderate hypertension
    Ueng, Kwo-Chang
    Lin, Lung-Chun
    Voon, Wen-Chol
    Lin, Ming-Cheng
    Liu, Yen-Bin
    Su, Ho-Ming
    Chang, Po-Yuan
    Lin, Tsung-Hsien
    Chen, Wei-Liang
    Wu, Chau-Chung
    Lai, Wen-Ter
    Lin, Chung-Sheng
    BLOOD PRESSURE, 2008, 17 : 24 - 31
  • [35] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
    Smolej, Lukas
    Brychtova, Yvona
    Cmunt, Eduard
    Doubek, Michael
    Spacek, Martin
    Belada, David
    Simkovic, Martin
    Stejskal, Lukas
    Zygulova, Irena
    Urbanova, Renata
    Brejcha, Martin
    Zuchnicka, Jana
    Mocikova, Heidi
    Kozak, Tomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778
  • [36] Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
    Jabbour, Elias
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Pemmaraju, Naveen
    Wierda, William
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Cortes, Jorge
    Garris, Rebecca
    Khoury, Joseph D.
    Jorgensen, Jeffrey
    Jain, Nitin
    Alvarez, Joie
    O'Brien, Susan
    Kantarjian, Hagop
    LANCET HAEMATOLOGY, 2018, 5 (12): : E618 - E627
  • [37] Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
    Gonzalez-Barca, Eva
    Canales, Miguel A.
    Salar, Antonio
    Ferrer, Secundino
    Domingo-Domenech, Eva
    Vidal, Maria-Jesus
    Grande, Carlos
    Bargay, Joan
    Gardella, Santiago
    Oriol, Albert
    Briones, Javier
    Garcia-Frade, Javier
    Bello, Jose L.
    Sanchez-Blanco, Jose J.
    Javier Penalver, Francisco
    Francisco Tomas, Jose
    Asensio, Antonio
    Lopez, Andres
    Caballero, Dolores
    ACTA HAEMATOLOGICA, 2016, 136 (02) : 76 - 84
  • [38] Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD plus C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT
    Dubreuil, Julien
    Houot, Roch
    Le Gouill, Steven
    Mounier, Christiane
    Courby, Stephane
    Dartigeas, Caroline
    Bouabdallah, Krimo
    Moles, Marie Pierre
    Magda, Alexis
    Tournilhac, Olivier
    Uribe, Mario Ojeda
    Bourre, Jean Cyril
    Bodet-Milin, Caroline
    Vuillez, Jean-Philippe
    Gressin, Remy
    BLOOD, 2014, 124 (21)
  • [39] Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
    Foussard, C
    Colombat, P
    Maisonneuve, H
    Berthou, C
    Gressin, R
    Rousselet, MC
    Rachieru, P
    Pignon, B
    Mahé, B
    Ghandour, C
    Desablens, B
    Casassus, P
    Lamy, T
    Delwail, V
    Deconinck, E
    ANNALS OF ONCOLOGY, 2005, 16 (03) : 466 - 472
1234